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Abstract
Tissue inhibitors of metalloproteinases (TIMPs) while originally characterized as inhibitors of matrix metalloproteinases
(MMPs) have recently been shown to have a wide range of functions that are independent of their MMP inhibitory
properties. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a potent inhibitor of VEGF-mediated angiogenesis and
neovascularization through its ability to block the binding of VEGF to its receptor VEGFR-2. To identify and characterize the
anti-angiogenic domain of TIMP-3, structure function analyses and synthetic peptide studies were performed using VEGF-
mediated receptor binding, signaling, migration and proliferation. In addition, the ability of TIMP-3 peptides to inhibit CNV
in a mouse model was evaluated. We demonstrate that the anti-angiogenic property resides in the COOH-terminal domain
of TIMP-3 protein which can block the binding of VEGF specifically to its receptor VEGFR-2, but not to VEGFR-1 similar to the
full-length wild-type protein. Synthetic peptides corresponding to putative loop 6 and tail region of TIMP-3 have anti-
angiogenic properties as determined by inhibition of VEGF binding to VEGFR-2, VEGF-induced phosphorylation of VEGFR-2
and downstream signaling pathways as well as endothelial cell proliferation and migration in response to VEGF. In addition,
we show that intravitreal administration of TIMP-3 peptide could inhibit the size of laser-induced choroidal
neovascularization lesions in mice. Thus, we have identified TIMP-3 peptides to be efficient inhibitors of angiogenesis
and have a potential to be used therapeutically in diseases with increased neovascularization.
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Introduction
Tissue inhibitors of metalloproteinases (TIMPs) constitute a
family of four proteins (TIMP-1, TIMP-2, TIMP-3 and TIMP-4)
that are endogenous inhibitors of matrix (MMP) and play a critical
role in the maintenance of extracellular matrix (ECM) homeosta-
sis. In general, all four TIMPs are broad-spectrum inhibitors of the
MMP family, with some differences in specificity. TIMP-3 has
been demonstrated to have a broader range of metalloproteinase
substrates being particularly effective in uniquely inhibiting several
members of the ADAM (a disintegrin and metalloprotease) and
ADAMTS (ADAM with thrombospondin motifs) family
[1,2,3,4,5,6]. Although originally characterized for their functional
property to inhibit MMP activity, TIMPs have more recently been
shown to have additional biological activities that may be
independent of their MMP-inhibitory functions [7]. We have
previously demonstrated that TIMP-3 is a potent angiogenesis
inhibitor, and functions independently of its MMP inhibitory
activity in this regard, by blocking the binding of vascular
endothelial growth factor (VEGF) to its receptor VEGFR-2 [8].
The three–dimensional structure analysis of TIMP-1 and
TIMP-2 revealed by X-ray crystallography identified the presence
of two distinct domains; a 125 amino acid N-terminal domain and
a 65 amino acid C-terminal domain, each stabilized by three
disulfide bonds [9]. In addition to an oligonucleotide and
oligosaccharide binding fold, the N-domain (which contains the
MMP inhibitory activity) contains a five-stranded closed twisted b-
barrel with a greek key topology and three a-helices. The C-
domain contains a pair of parallel b strands associated with a loop
followed by a helix and a pair of antiparallel b strands linked by a
b-hairpin [10]. To identify the anti-angiogenic functional domains
of TIMP-3, we performed a series of structure-function analyses
examining VEGF binding to VEGFR-2, and downstream
endothelial cell proliferation and migration. We determined that
the COOH-terminal domain of TIMP-3 contains the angio-
inhibitory activity with the NH2-terminal domain being inert for
this function. We further mapped the ability to block VEGF
binding to VEGFR-2 to the ‘‘loop 6’’ and ‘‘tail’’ peptides and the
capability of ‘‘loop 6’’ to inhibit choroidal neovascularization
(CNV) in a rodent model.
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Materials and Methods
Materials
Porcine Aortic Endothelial cells expressing VEGFR-2
(PAEKDR) were cultured in Ham’s F-12/DMEM medium
supplemented with 10% fetal bovine serum (FBS) (Hyclone), 50
units/ml penicillin and 50 mg/ml streptomycin as described
previously [11]. Recombinant human VEGF was a kind gift from
Genentech, CA. Antibodies: Anti-Phosphotyrosine clone 4G10
(Upstate Biotechnology/Millipore, Billerica, MA), monoclonal
anti-Flk-1 (A-3) (Santa Cruz Biotechnology, Santacruz, CA),
MAPK and phospho-specific MAPK antibodies (Calbiochem-
Novabiochem Corporation/EMD chemicals, Gibbstown, NJ).
Generation and Purification of Recombinant TIMP-3
Proteins
Full length, recombinant human TIMP-3 was purified from
stably transfected mouse myeloma cells as described previously
[12]. The human N-TIMP-3 expression vector was designed as
fusion protein encompassing amino acids 1–115, with an extension
of 25 amino acids at the C-terminus (Val-Asp-Ala-Ala-Ala-Glu-
Gln-Lys-Leu-Ile-Ser-Glu-Glu-Asp-Leu-Asn-Gly-Ala-Ala–His-His-
His-His-His-His) and the protein purified and refolded following
transformation of ultracompetent E.coli BL21(DE3) as described
previously [13].The N-TIMP2/C-TIMP-3 chimera was construct-
ed using overlapping extension PCR. The amplified N terminal
domain of TIMP-2 (residues 1–127) and the C-terminal domain of
TIMP-3 (residues 122–188) were combined and subjected to PCR
using a forward primer complementary to the N-TIMP-2 and a
reverse primer complementary to the end of C-TIMP-3. The
resulting N-TIMP-2-C-TIMP-3 cDNA was cloned into
BL21(DE3)pLysS E. coli and large scale cultures grown as
described for N-TIMP-3 [13]. Following ITPG (Isopropyl-b-D-
thio-galactoside) induction, inclusion bodies were sheared in Tris
buffered saline, 1%Tween-20 and sonicated. Subsequent to
centrifugation, the pellets were washed in 1 M urea and ddH2O.
After protein concentration estimations, the protein was suspended
in solubilization buffer and then subjected to a refolding protocol
with refolding buffer (0.45 M GuHCl, 100 mM Tris-HCl,
pH 8.75, 0.8 mM GSH, 0.45 mM GSSG) and allowed to stir
overnight at 4uC. The refolded protein was dialysed against 2
changes of 40 L of 10 mM acetate, pH 6.0 and centrifuged
(15 min, 10000 rpm) to remove precipitate. The cleared protein
solution was loaded under gravity onto a 30 ml SP-Sepharose
column (Sigma S-1799) pre-equilibrated in 10 mM Na Acetate,
pH 6.0. The column was washed with 3 volumes of the same
buffer and the protein eluted using 50 mM Tris-HCl, pH 7.5,
0.5 M NaCl, 20%glycerol. Samples of purified protein were
compared under reducing and non-reducing conditions by
combining the protein with the appropriate sample buffer and
loading them on a 12.5% SDS-PAGE gel with MW markers. N-
TIMP-2-C-TIMP-3 was active-site titrated against MMP2, with
total protein concentrations estimated using A280 readings.
Peptide Synthesis
The peptides were synthesized by Fmoc strategy on an Omega
396 synthesizer (Advanced ChemTech, Louisville, KY) using solid
phase chemistry. Preloaded Fmoc-Wang resin and Fmoc-L-amino
acids were procured from Anaspec (San Jose, CA). The peptide
synthesis was performed by double coupling amino acid esters of
1-hydroxybenzotriazole (HOBt) using 1,3 diisopropylcarbodiimide
(DIC) as the coupling agent. A six-fold excess of N-alpha-Fmoc
amino acid esters of HOBt in NMP were used in the synthesis. A
1:1 ratio of amino acid to DIC was used in all the coupling
reactions. Deprotection of N-alpha-Fmoc group was accomplished
by 25% piperidine in dimethylformamide twice; first for 5 minutes
and than a second time for 25 minutes. After the synthesis was
completed, the peptides were cleaved from the solid support and
deprotected using a modified reagent K(r) cocktail consisting of
88%TFA, 3%thioanisole, 5% ethanedithiole, 2%water and 2%
phenol. Four mls of cleavage cocktail was added to the dried
peptide-resins in a 15 ml glass vial blanketed with nitrogen and
cleavage was carried out for 2.5 hrs with gentle magnetic stirring.
At the end cleavage time, the cocktail mixture was filtered on a
Quick-Snap column. The filtrate was collected in 20 ml ice-cold
butane ether. The peptides were allowed to precipitate for an hour
at 220uC, centrifuged, and washed twice with ice-cold methyl-t-
butyl ether. The precipitate was dissolved in 25% acetonitrile and
lyophilized to complete dry powder.
Quality of peptides was analyzed by analytical reverse phase
HPLC and MALDI-TOF-TOF (matrix assisted laser desorption
ionization time-of-flight) Mass Spectrometer, model 4800 from
Applied Biosystems. The peptide was purified on TARGA C18
semi-preparative column (250610 mm) from Higgins Analytical
Inc.,USA.
Peptide sequences were designed to represent various smaller
structural domains of the carboxyl terminus of TIMP-3. These
include: a 10-amino acid peptide corresponding to loop 5 with
sequence (KIKSCYYLPCFVTS), a 24-amino acid peptide corre-
sponding to loop 6 with sequence (KNECLWTDMLSNFGYP-
GYQSKHYACIRQKG), and a 19-amino acid peptide corre-
sponding to the carboxy-terminal tail with sequence
(GYCSWYRGWAPPDKSIINATDP). A fourth peptide of se-
quence (RGFTKMPHVQYIHTEASESL) corresponding to a
conserved sequence in the NH2-terminal domain of all TIMPs
was also synthesized.
Competitive ELISA
96 well EIA/RIA strip plates (COSTAR) were coated with
80 ng/ml recombinant VEGF overnight at 4uC, washed and
blocked with blocking buffer (1% BSA and 5% sucrose) overnight
at 4uC. Series of dilutions were prepared for recombinant proteins
representing WT-TIMP-3, NT2:CT3 and N-T3 in PBS or
synthetic peptides corresponding to T3-loop 5, T3-loop 6, T3-N
or T3-tail peptides in 0.5 M Tris-HCl (pH 7.5). The diluents were
mixed with 50 ng/ml recombinant human VEGFR-2 (KDR/Fc
chimera, recombinant human VEGFR-1 (Flt-1)/Fc chimera
(R&D Systems, Minneapolis, MN) or control human lgG (Sigma
Aldrich, St Louis, MO). The mixtures were then added to the
VEGF-coated well in a final volume of 100 mL in PBS and
incubated for 2 hours at room temperature. Bound VEGFR-2 was
detected by HRP-conjugated anti-human lgG(Fc specific) (1:1000).
Immunoprecipitation and Immunoblotting
Immunoprecipitates of cell lysates with the indicated antibodies
were subjected to SDS-PAGE and western blot analysis. Proteins
were detected with either a HRP-conjugated anti-rabbit or anti-
mouse IgG antibody (Amersham Pharmacia Biotech., Piscataway,
NJ) followed by ECL. The blots were restripped with Western
ReProbeTM solution (GBiosciences, Maryland Heights, MO) for
30 minutes and reprobed as indicated.
Immunofluorescence Staining Analyses
Subconfluent cells cultured on Falcon culture slides (BD
Biosciences) were serum-starved overnight and stimulated for
30 min at 37uC with 50 ng/ml VEGF or control buffer. The cells
were fixed with 3.7% paraformaldehyde in PBS for 30 min at 4uC
and permeabilized with 0.2% Triton X-100 for 20 min at room
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Figure 1. The effects of recombinant wild type TIMP-3 (WT-TIMP-3), N-terminal TIMP2: C-terminal TIMP-3 chimera (NT2: CT3) and
the NH3-terminal domain of TIMP-3 (NT3) on binding of 50 ng/ml soluble(s) VEGFR-1 or VEGFR-2 to immobilized VEGF. A
competitive ELISA assay was used as described under ‘‘Materials and Methods’’. (a) description of WT-TIMP-3, N-T3 and NT2:CT3 (b). WT-TIMP-3 and
NT2: CT3 inhibit sVEGFR-2-VEGF complexes in a concentration-dependent manner. (c). N-T3 has no effect on sVEGFR-2-VEGF complexes. (d). WT-
TIMP-3, NT2 and N-T3 are unable to block sVEGFR-1-VEGF complexes.
doi:10.1371/journal.pone.0055667.g001
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temperature. Following rinsing with PBS, the cells were incubated
with fluorescein isothiocyanate (FITC)-labeled phalloidin in PBS
(0.66 mg/ml, Sigma Aldrich, St. Louis, MO) for 20 min at room
temperature, washed with PBS and analyzed by fluorescence
microscopy.
Migration Assay
A modified Boyden chamber assay was performed as described
previously [8]. Briefly, 8.0 mm pore PVPF polycarbonate mem-
branes were pre-coated with 100 mg/ml collagen type I in 0.2 N
acetic acid (Cohesion technologies, Inc. Palo Alto, California).
VEGF at the indicated concentrations was placed in the lower
chamber, and cells (26105) in serum-free medium were placed in
the upper chambers. The chamber was then incubated for 4 hrs at
37uC in a 5% CO2, humidified incubator. Cells remaining on the
top of the filter were removed. Cells on the bottom surface of the
filter were fixed (in 10% formalin), stained (Hematoxilin) and
mounted (in Permount). The number of migrating cells per well
was evaluated by light microscopy.
Proliferation Assay
Cells were seeded at a density of 2000 cells/well in 24 well
culture plates and cultured for 24 h in growth medium. After
synchronization overnight in serum-free medium supplemented
with 0.1% BSA, the cells were stimulated with or without VEGF
for 36 h in the presence or absence of the indicated concentrations
of TIMP-3 peptides. After a 5-day incubation, cells were
trypsinized and counted using a Coulter particle counter.
Laser-induced CNV Assay
All animal studies were approved by the Animal Care and Use
Committee of the Cleveland Clinic (IACUC number ARC-08792)
and conformed to the National Institutes of Health Guide for the
Care and Use of Animals in Research and the ARVO statement
for the use of animals in ophthalmic and vision research. All
surgery was performed under ketamine/xylazine anesthesia with
maximum effort devoted to minimizing suffering. Laser photoco-
agulation-induced rupture of Bruch’s membrane was used to
generate CNV as previously described [14]. Briefly, 4–5 week old
C57BL/6J mice were anesthetized with ketamine hydrochloride
(100 mg/kg body weight) and xylazine (10 mg/kg body weight)
followed by1% Tropicamide (Alcon laboratories, Inc., Fort Worth,
TX) for pupillary dilation. Three burns of 532-nm diode laser
photocoagulation (Oculight; Iridex, Mountain View California;
50-mm spot size, 0.1 second duration, 200 mW) were delivered to
each retina using a slit lamp delivery system and a hand held
coverslip as a contact lens. Burns were performed in the 9, 12 and
3 o’clock positions of the posterior pole of the retina. Production of
a bubble at the time of lasering indicated a successful burn. At the
same time, intravitreal injections of TIMP-3 peptides or control
PBS was performed. Two weeks later, mice were anesthetized and
perfused with fluorescein-labeled dextran (26106 average molec-
ular weight, Sigma Aldrich), choroidal flatmounts were prepared
and CNV area measured. For the experiments using tail peptide,
the animals were visualized by confocal scanning laser ophthal-
moscope (cSLO, HRA2, Heidelberg Engineering, Inc.) following
Fluorescein angiography(FA) The imaging field-of view was 55
degrees.
Five mice were used for each dose of peptide, with three burns
in each eye (n = 15–18 successful burns in each group). For
quantitative analysis of lesion intensity and size, CNV images were
batch processed using a custom macro generated in Image-Pro
Plus 5.1 (Media Cybernetics, Silver Spring, MD). For each image,
a region of interest (ROI) was traced around the lesion using a
wand tool (a manual trace was performed in a few cases where the
lesion was not significantly brighter than the background). Mean
intensity (range between 10–255 gray levels), perimeter, area, and
mean diameter (pixels) were calculated for each ROI and exported
to excel. Analyses were performed in a blinded fashion to eliminate
user bias.
Statistical Analysis
Data are presented as mean6 SD. The statistical significance of
differential findings observed between experimental and control
groups were determined using one-way analysis of variance
(ANOVA) and considered to be significant if P values were ,0.05.
Results
COOH-terminal TIMP-3 Domain Inhibits VEGF Binding to
VEGFR-2
NH2 terminal TIMP-3 protein [N-T3] (residues 1–121) and an
NH2-terminal TIMP-2: COOH-terminal TIMP-3 chimera
[NT2:CT3] representing the isolated C-terminal domain of
TIMP-3 (residues 1–126 of TIMP-2 and residues 122–188 of
TIMP-3) (Fig. 1a) were purified as described previously [15].
We performed a competitive ELISA to test the ability of WT
TIMP-3, N-T3 and NT2:CT3 to block the binding of VEGF to its
receptors VEGFR-2 and VEGFR-1. Soluble VEGFR-2/Fc
chimera (sVEGFR-2/Fc chimera) bound to VEGF immobilized
on ELISA plates in a concentration dependent manner (data not
shown). In the presence of recombinant WT-TIMP-3 protein and
NT2:CT3, the binding of VEGF to sVEGFR-2/Fc chimera was
markedly decreased (IC50 value of 41 nM and 28 nM respective-
ly) (Fig. 1b). In contrast, the addition of recombinant N-T3 did not
disrupt the formation of VEGF-VEGFR-2 complexes (Fig. 1c)
indicating that the anti-angiogenic activity of TIMP-3 is present in
the COOH-terminal domain. In addition, the ability to block the
binding of VEGF to its receptor is specific for VEGFR-2 as neither
full length WT-TIMP-3 nor COOH-terminal TIMP-3 blocked
the binding of VEGF to VEGFR1 (sFlt-1) (Fig. 1d).
Preparation of COOH-terminal TIMP-3 Peptides
To further map the anti-angiogenic activity of TIMP-3 within
its COOH-terminal domain, four peptides corresponding to
various smaller domains of T3 were synthesized. COOH-terminal
peptides of TIMP-3 were prepared by solid-phase peptide
synthesis using Fmoc-protected amino groups. The final purifica-
tion was performed using a TARGA-C18 semi-preparative
column and electrospray ion trap mass spectrometry was used to
determine the average molecular mass (Mr). NH2-terminal
sequencing in addition to MS confirmed the purity and molecular
mass of the peptides. The Mrs and sequences of the purified
peptides are indicated in Table 1.
T3-loop 6 and T3-tail Peptides Inhibit the Binding of
VEGF to sVEGFR-2
VEGF-A signals primarily via the VEGF-receptor tyrosine
kinases, VEGFR-1 and 2, with VEGFR-2 being implicated as the
predominant pro-angiogenic receptor. The role of VEGFR-1 has
been more controversial with some data demonstrating it as
having a pro-angiogenic role [16] and others an anti-angiogenic
function [17]. The T3-peptides were initially tested for their ability
to block the binding of VEGF to sVEGFR-2/Fc chimera in an
in vitro competitive ELISA. T3-loop 6 and T3-tail could inhibit
binding of VEGF to sVEGFR-2/Fc chimera (Fig. 2a) in a
concentration dependent fashion with an IC50 of 2 and 5 mM
TIMP3 Peptides Inhibit Ocular Neovascularization
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respectively. In contrast, two peptides corresponding to T3-loop 5
and the NH2-terminal domain of intact TIMP-3 (N-peptide) did
not show any inhibitory activity (Fig. 2b). Interestingly, the IC 50
of the small peptides was in the mM range compared with the nM
range doses seen with the entire COOH-terminal T3 domain. In
addition, as observed with the COOH-terminal T3 domain, T3-
loop 6 and T3-tail did not inhibit VEGF binding to VEGFR-1
(Flt-1) (Fig. 2c). Whether pan-inhibition of VEGF is necessary for
inhibition of neovascularization or if inhibition of signaling via
VEGFR-2 is sufficient has not been ascertained. Based on our
results with TIMP-3 peptides we postulated that the TIMP-3
would be a useful tool to determine if specific inhibition of binding
of VEGF to VEGFR-2 could inhibit VEGF-mediated angiogen-
esis.
T3-loop 6 and T3-tail Peptides Inhibit VEGFR-2 Signaling
in Endothelial Cells
We examined whether T3-loop 6 and T3-tail could regulate
signaling events that follow VEGF binding to VEGFR-2 in
endothelial cells (PAE/KDR). Prior to treatment with the T3-
peptides at various concentrations, serum-starved endothelial cells
were stimulated with VEGF. Immunoprecipitation of VEGFR-2
followed by western blot analysis with anti-phosphotyrosine
antibodies was performed to evaluate the autophosphorylation of
VEGFR-2 by VEGF in the presence of T3 peptides. As shown in
Figure 2. The effect of synthetic TIMP-3 peptides on binding of 50 ng/ml soluble (s) VEGFR-1 or –2 to immobilized VEGF. A
competitive ELISA assay was used as described under ‘‘Materials and Methods’’ (a). Loop 6 and tail peptides inhibit sVEGFR-2-VEGF complexes in a
concentration-dependent manner. (b) Loop5 and N-peptide have no effect on sVEGFR-2-VEGF complexes. (c) Loop 5, loop 6, tail and N-peptide are
unable to inhibit sVEGFR-1-VEGF complexes.
doi:10.1371/journal.pone.0055667.g002
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Fig. 3a, a mature form of VEGFR-2 corresponding to a molecular
size of 210-kDa was phosphorylated in control cells following
treatment with VEGF. Treatment of endothelial cells with 10 mM
T3-loop 6 or T3-tail peptide resulted in a significant inhibition of
VEGF-induced receptor autophosphorylation (Fig. 3a, upper
panel). Western blot analysis of the same blot with antibodies
directed against the C-terminus of VEGFR-2, determined that
there was no effect of the peptides on VEGFR-2 levels on the
surface of endothelial cells (Fig. 3a, lower panel). To quantitate
phosphorylation of VEGFR-2, densitometry of the phosphorylated
Figure 3. Effects of TIMP-3 peptides on VEGF signaling in endothelial cells. (a) TIMP-3 loop 6 and tail inhibit VEGF-mediated
phosphorylation of VEGFR-2 in PAE/KDR cells in a concentration dependent manner. Prior to treatment with indicated concentrations of TIMP-3
peptides for 30 min, the serum-starved cells were stimulated or not with 50 ng/ml VEGF for 10 min in the presence or absence of the same
concentration of peptide. Cell lysates were separated by SDS-PAGE (10%) and analyzed by immunoprecipitation with an anti-KDR anti-body followed
by immunoblotting with an anti-phosphotyrosine antibody, 4G10 (top panel). KDR protein was analyzed by immunoprecipitation and
immunoblotting of cell lysates using anti-KDR antibody (bottom panel). (b) Densitometric quantitation of 210-kDa bands for phospho- or total
mature form of KDR. (c) TIMP-3 loop 6 and tail but not loop 5 and N-peptide inhibit VEGF-mediated phosphorylation of KDR in PAE/KDR cells. (d)
TIMP-3 loop 6 and tail inhibit ERK phosphorylation. Phosphorylation of ERK1 and ERK2 in response to VEGF was detected by immunoblotting with
phosphospecific MAP kinase antibodies (top panel). Total protein levels of ERK was determined by immunoblotting with anti- MAP kinase antibodies
(bottom panel). (e) TIMP-3 loop 6 and tail but not loop 5 nor N-peptide inhibit VEGF-mediated phosphorylation of ERK in PAE/KDR cells.(f)
Densitometric quantitation of pERK (top panel of d) and ERK bands (bottom panel of d) for phospho- or total ERK proteins. **significantly different
from control (without peptides+VEGF), p,0.01 (Student’s t test).
doi:10.1371/journal.pone.0055667.g003
Figure 4. Effects of TIMP-3 peptides on VEGF-mediated EC migration. TIMP-3 loop 6 and tail but not loop 5 and N-peptide inhibit VEGF-
induced migration in PAE/KDR cells. Cells were analyzed for migration towards 50 ng/ml VEGF in the presence or absence of increasing
concentrations of loop 6 (a) and tail peptides (b) or 20 mM loop 5 or N-peptide (c), respectively, using a mini-Boyden chamber incubated at 37uC for
4 h. Migrating cell number is expressed as means6 SEM of quadruplicate samples. **significantly different from control (without peptides), p,0.01
(Student’s t test).
doi:10.1371/journal.pone.0055667.g004
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Figure 5. Effects of TIMP-3 peptides on VEGF-mediated actin reorganization. TIMP-3 loop 6 and tail but not loop 5 and N-peptide inhibit
VEGF-induced actin reorganization in PAE/KDR cells. Quiescent cells were stimulated with (b,c,g,h,i,m,n,o,r,s) or without (a,d,e,f,j,k,l,p,q) 50 ng/ml
VEGF in the presence or absence of increasing concentrations of loop 6 (d-i) and tail peptides (j-o) or 20 mM loop 5 (q,s) or N-peptides (p,r) for 30 min
at 37uC. Cells were permeabilized and stained with fluorescein isothiocyanate-phalloidin, as described under ‘‘Materials and Methods’’. The arrows
indicate membrane edge ruffling in the stimulated cells. Magnification,61000.
doi:10.1371/journal.pone.0055667.g005
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VEGFR-2 band (pVEGFR-2) as well as the total VEGFR-2 band
(KDR) was performed. The ratio of pVEGFR-2:VEGFR-2 was
determined and compared between peptide treatments (Fig. 3b).
20 mM T3-loop 5 or T3-N peptide failed to inhibit VEGF-induced
receptor activation (Fig. 3c).
Activation of MAP kinase is a known VEGFR-2 downstream
signaling event. We analyzed the effect of TIMP-3 peptides on the
phosphorylation of MAP kinases, ERK1 (p44) and ERK2 (p42), in
endothelial cells exposed to VEGF by western blot analysis. Fig. 3d
shows T3-loop 6 or T3-tail peptides inhibited VEGF-stimulated
phosphorylation of ERK1/2 (Fig. 3d,f). In contrast, neither loop 5
nor N-peptide, even at higher concentrations (20 mM) inhibited
VEGF-stimulated MAP kinase activation (Fig. 3e).
T3-Loop 6 and T3-tail Peptides Inhibit VEGF-stimulated
Endothelial Cell Migration and Actin Reorganization of
PAE/KDR Cells
Migration of endothelial cells is essential for angiogenesis. We
tested the TIMP-3 peptides for their ability to block chemotaxis of
endothelial cells to VEGF using a Boyden mini-chamber assay.
T3-loop 6 (Fig. 4a) and T3-tail (Fig. 4b) significantly inhibited
VEGF-induced migration at doses of 1, 10 and 20 mM.
Interestingly, basal migration in the absence of VEGF was not
inhibited by these peptides. In contrast, loop 5 and N-peptide at
doses of up to 20 mM failed to inhibit VEGF-induced migration
(Fig. 4c).
Endothelial cell migration involves reorganization of the actin
cytoskeleton with the formation of membrane edge ruffles, that
have previously been shown to be an integral part of cell motility
responses. We analyzed the effects of the TIMP-3 peptides on
VEGF-stimulated formation of membrane ruffles, in endothelial
cells. As previously described [18], membrane ruffles were induced
in a majority of endothelial cells following VEGF stimulation for
30 min (Fig. 5b and 5c). Pretreatment with T3-loop 6 or T3-tail
peptides at doses of 10 mM and 20 mM significantly inhibited the
VEGF-stimulated induction of membrane ruffles (Figs. 5h, 5i, 5n,
5o). In contrast, neither T3-loop 5 nor T3-N peptide at doses as
high as 20 mM inhibited the formation of membrane ruffles (Fig. 5r
and 5s).
T3-loop 6 and T3-tail, but not T3-loop 5 Peptides Inhibit
the VEGF-induced Proliferation of Endothelial Cells
Proliferation of endothelial cells is a critical component of
angiogenesis. We examined the ability of TIMP-3 peptides to
suppress VEGF-induced proliferation of endothelial cells. Quies-
cent cells were incubated with VEGF in the presence or absence of
peptides. We determined that T3-loop 6 and T3-tail peptides
inhibited VEGF-stimulated endothelial cell proliferation at doses
as low as 1 mM. Under similar conditions, neither T3-loop 5 nor
T3-N peptide showed inhibitory properties(Fig. 6) and may in fact
induce proliferation of endothelial cells.
T3-loop 6 and T3-tail Peptides Inhibit Choroidal
Neovascularization (CNV) in an in vivo Mouse Model
CNV was induced in mice following laser injury of Bruch’s
membrane. In order to determine if TIMP-3 peptides could
inhibit CNV we performed a single intravitreal injection of TIMP-
3 peptides at various doses immediately following the laser burn.
Mice were analyzed for the development of choroidal neovascular
membranes 14 days later. Quantitative image analysis determined
that T3-loop 6 (Fig. 7d) could significantly inhibit the area of CNV
in mice (Fig. 7h) when compared with the CNV lesions from
uninjected (Fig.7a), PBS (Fig. 7b,7e), T3-loop5 (data not shown) or
T3-N peptides (Fig. 7c, g) injected animals. T3-tail peptides (Fig. 7f,
7i) showed a similar trend with 2 doses (10 mg and 50 mg) but not
at the 100 mg dose (Fig. 7i). The effect of the tail peptides on laser-
induced CNV was evaluated by fluorescein angiogram and
scanning laser ophthalmoscopy with similar results (Fig. 7e, 7f,
7i). Injection of peptide alone in the absence of laser burn did not
induce any pathology in the retina (data not shown).
Discussion
The sprouting of new blood vessels from pre-existing vascula-
ture, termed angiogenesis, contributes significantly to a number of
pathological conditions such as cancer, diabetes and age-related
macular degeneration. This process of neovascularization is kept
in check by the tight regulatory balance between pro- and anti-
angiogenic factors. The extracellular matrix (ECM) plays a critical
role in the regulation of angiogenesis with matrix degrading
enzymes having been shown to generally be pro-angiogenic and
endogenous MMP inhibitors (TIMPs), anti-angiogenic. However,
MMP-mediated controlled proteolysis of the ECM, also releases
protein fragments such as endostatin, canstatin, tumstatin, and
endorepellin that are biologically active and potent angiogenesis
inhibitors [10,19]. For a number of years, the tumor-inhibitory
and anti-angiogenic properties of TIMPs were believed to be
entirely due to their MMP inhibitory properties. As a conse-
quence, there has been a considerable investment of resources to
develop safe and effective therapeutic modalities that target
MMPs. Several generations of synthetic MMP inhibitors were
tested in phase III clinical trials in humans but were found to be
surprisingly ineffective relative to the results obtained in pre-
clinical trials [20].
More recently, TIMPs have been shown to be multifunctional
proteins with a number of biological activities that were
independent of their MMP inhibitory properties [7]. Inhibition
of angiogenesis by TIMP-2 and TIMP-3 has been demonstrated to
be independent of their ability to inhibit MMPs [8,21,22].
Previously described studies of the structure-functional analyses
of TIMP-2 revealed that the anti-angiogenic activity of TIMP-2
Figure 6. Effects of TIMP-3 peptides on VEGF-mediated EC
proliferation. TIMP-3 loop 6 and tail but not loop 5 and N-peptide
inhibit VEGF-induced proliferation in PAE/KDR cells. Serum-starved cells
were incubated with or without VEGF (5 ng/ml) in the presence or
absence of the 1 mM of TIMP-3 peptides for 5 days. Cell numbers were
counted using a Coulter particle counter. **significantly different from
control (with VEGF), p,0.01 (Student’s t test).
doi:10.1371/journal.pone.0055667.g006
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was present in the C-terminal end specifically in a smaller, 2.9 kDa
domain in this region (Loop 6) [21]. Based on these studies we
designed experiments to determine the region of TIMP-3 that was
responsible for angiogenesis inhibition. In the present study we
identified the C-terminal region of the protein to be responsible for
this effect, using the property of TIMP-3 to block binding of
VEGF to VEGFR-2 [8]that we had previously reported. Short
peptides were designed based on the functional domains of TIMP-
1 [23]. We mapped the anti-angiogenic activity of TIMP-3 to
peptides in the putative Loop 6 and Tail regions of the protein
(Figure 8). Peptides based on the Loop 5 and N-terminal domains
had no angio-inhibitory activity in vitro or in vivo. Concomitant-
ly, Loop6 and Tail peptides were effective in inhibiting laser-
induced CNV in vivo.
Sorsby fundus dystrophy (SFD), an autosomal dominant, fully
penetrant, degenerative disease of the macula [24,25] is manifest-
ed by symptoms of night blindness or sudden loss of acuity, usually
in the third to fourth decades of life due to submacular
Figure 7. Inhibition of laser-induced CNV by TIMP-3 peptides. TIMP-3 loop 6 and tail but not N-peptide inhibit laser-induced CNV in a mouse
model. Representative images of mouse choroids at 14 days following laser photocoagulation in C57BL6 mice (a) untreated/uninjected (b) injected
with PBS control (c) T3N (d) T3-Loop6 (e) injected with PBS contro (f) T3-tail. Effect of Tail peptides on CNV was evaluated by Fluorescein angiogram
and Scanning Laser Ophthalmoscopy (SLO). Peptides were injected intravitreally immediately following laser burn. CNV lesion size (area X density)
was calculated for each dose of T3N-peptide (Fig. 7g), Loop6-peptide (Fig. 7h) and Tail-peptide (fig. 7i).
doi:10.1371/journal.pone.0055667.g007
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neovascularization [26,27,28,29]. SFD is caused by specific
mutations in the tissue inhibitor of metalloproteinases-3 (TIMP-
3) gene [30,31,32,33,34,35,36,37], most of which introduce an
unpaired cysteine at the C-terminus of the protein. We have
recently reported that S156C mutation in TIMP-3 induces
increased angiogenesis [18] and that mice lacking TIMP-3 show
increased laser-induced CNV [38]. Since the anti-angiogenic
activity of TIMP-3 (and TIMP-2) [21] lies in the C-terminus
region of the protein and most of the new cysteines in SFD
mutations lie in the same region (Fig. 8) we hypothesized that
Loop 6 and Tail peptides of TIMP-3 might be critical
determinants of this inhibitory activity. Whether the free cysteine
in the tail peptide sequence is critical for the angiogenesis
inhibition will be an interesting question to address in future
studies. Sequence comparison and alignment between a short
peptide sequence of pigment epithelial growth factor (PEDF) that
shows anti-angiogenic activity and TIMP-3 shows a short
consensus sequence of SNFGYXXY between the two proteins
[39]. Both PEDF and TIMP-3 are anti-angiogenic proteins whose
peptides have been shown to play a critical role in inhibiting ocular
angiogenesis especially choroidal neovascularization. Finding
consensus sequences in these peptides might provide clues
regarding the mechanisms of inhibition of neovascularization.
VEGF plays an important role in the maintenance and function
of the adult retina neuronal cells [40]. KDR has been
demonstrated to be involved mainly in pathological angiogenesis.
Immunohistochemical localization studies of VEGF receptors in
the retina have determined VEGFR-2 to be expressed minimally
in normal retina and significantly increased in both intra-and pre-
retinal vessels in PDR tissue [41]. This same study showed that
VEGFR-1 was present in normal retina and confined to the inner
nuclear layer, ganglion cell layer and retinal vessels and
significantly increased in diabetic retinas. While the exact function
of VEGFR-1 has not been elucidated it has been postulated to play
a role in endothelial cell homeostasis. Thus inhibiting signaling via
VEGFR-1 may have a detrimental effect on the normal
physiological function of endothelial cells. Thus a selective agent
that can block VEGF signaling exclusively via the VEGFR-2 may
have less long-term toxicity issues than a broad spectrum VEGF
inhibitor.
Alanine scanning mutagenesis identified residues in the loop III
region formed by the anti-parallel b sheets in VEGF protein to be
responsible for binding to VEGFR-2. Blocking of VEGFR-ligand
interaction has been a validated approach in drug development for
CNV, as seen with the clinical success of bevacizumab (Avastin)
and ranibizumab (Lucentis) in AMD. While the exact molecular
mechanism(s), by which TIMP-3 peptides inhibit VEGF-mediated
neovascularization have not yet been elucidated, they appear to be
good candidates for drug design as they demonstrate remarkable
specificity for inhibition of VEGF binding to VEGFR-2 with no
effect on its binding to VEGFR-1.
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